Robert Lapetina is a seasoned finance executive with more than 25 years of experience in the biotechnology and pharmaceutical industries. He served as Interim Principal Financial and Accounting Officer at CG Oncology Inc., a clinical-stage biotechnology company developing oncolytic immunotherapies for bladder cancer. In this role from early 2023 until the appointment of a permanent officer, Lapetina oversaw all financial reporting, accounting operations, internal controls, and compliance efforts during a pivotal period that included advancing the Phase 3 CREST trial for the company's lead candidate, cretostimogene grenadenorepvec, and preparing for potential regulatory milestones. Prior to CG Oncology, Lapetina held senior finance leadership positions at several prominent biotech firms, including Vice President of Finance at Aduro Biotech and Controller at BioMarin Pharmaceutical. His career also encompasses roles at Deloitte & Touche, where he honed his expertise in audit and advisory services for life sciences clients. Lapetina is a Certified Public Accountant (CPA) and holds a Bachelor of Science in Accounting from San Diego State University. Throughout his career, Lapetina has been instrumental in guiding companies through complex financial challenges, including successful IPOs, mergers and acquisitions, and cost-optimization initiatives that have delivered multimillion-dollar savings. His strategic acumen and deep knowledge of SEC regulations have earned him a reputation as a trusted advisor in the biotech sector, contributing to sustainable growth and operational excellence at each organization he has served.